Celebrating Spyre Therapeutics on their positive interim Phase 1 results for SPY002 and SPY072 - two next generation anti-TL1A antibodies. Looking forward to what's ahead!
Today, we’re pleased to share positive interim results from our Phase 1 trials of SPY002 and SPY072, two novel, extended half-life anti-TL1A antibodies. Each trial was a first-in-human, randomized, double-blind, placebo-controlled study evaluating safety, PK and PD. Additionally, interim data for both programs through 20 weeks of follow up: · Showed both antibodies were well tolerated across all dose levels · PK supports quarterly or less frequent dosing · Showed full TL1A target engagement for up to 20 weeks · Met key Phase 1 objectives and are advancing to Phase 2, SPY002 in #IBD and SPY072 in #rheumatology We are also proud to become a Phase 2 biotech company with the initiation of our SKYLINE-UC platform trial evaluating three monotherapies and three combinations in ulcerative colitis and the introduction of our planned SKYWAY-RD basket trial, which will evaluate SPY072 in three rheumatologic indications. We anticipate nine Phase 2 readouts between 2026 and 2027. Read more in the PR, including our forward-looking statements legend, and join us for a webcast for more details today at 8AM ET. https://lnkd.in/eFfMYnEY
